The invention relates to a humanized anti-B7-2 antibody that comprises a
variable region of nonhuman origin and at least a portion of an
immunoglobulin of human origin. The invention also pertains to methods of
treatment for various autoimmune diseases, transplant rejection,
inflammatory disorders and infectious diseases by administering humanized
anti-B7-2 and/or anti-B7-1 antibodies.
